BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 33662776)

  • 1. Local treatment of pancreatic cancer metastases: A multicenter French study of the AGEO group.
    Breton C; Meyer A; Malka D; Matias M; De Baere T; Hammel P; Sa Cunha A; Lucchese A; Fuks D; Coriat R; Gallois C; Touchefeu Y; Maillet M; Trouilloud I; Rompteaux P; Carbonnel F; Soularue E
    Clin Res Hepatol Gastroenterol; 2021 Nov; 45(6):101607. PubMed ID: 33662776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different clinical presentations of metachronous pulmonary metastases after resection of pancreatic ductal adenocarcinoma: Retrospective study and review of the literature.
    Lovecek M; Skalicky P; Chudacek J; Szkorupa M; Svebisova H; Lemstrova R; Ehrmann J; Melichar B; Yogeswara T; Klos D; Vrba R; Havlik R; Mohelnikova-Duchonova B
    World J Gastroenterol; 2017 Sep; 23(35):6420-6428. PubMed ID: 29085191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oligometastatic pulmonary metastasis in pancreatic cancer patients: Safety and outcome of resection.
    Ilmer M; Schiergens TS; Renz BW; Schneider C; Sargut M; Waligora R; Weniger M; Hartwig W; Ceyhan GO; Friess H; Werner J; D'Haese JG
    Surg Oncol; 2019 Dec; 31():16-21. PubMed ID: 31473583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The indolent nature of pulmonary metastases from ductal adenocarcinoma of the pancreas.
    Downs-Canner S; Zenati M; Boone BA; Varley PR; Steve J; Hogg ME; Zureikat A; Zeh HJ; Lee KK
    J Surg Oncol; 2015 Jul; 112(1):80-5. PubMed ID: 26153355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between primary origin (head, body and tail) of metastasised pancreatic ductal adenocarcinoma and oncologic outcome: A population-based analysis.
    Mackay TM; van Erning FN; van der Geest LGM; de Groot JWB; Haj Mohammad N; Lemmens VE; van Laarhoven HW; Besselink MG; Wilmink JW;
    Eur J Cancer; 2019 Jan; 106():99-105. PubMed ID: 30476732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Site of relapse of ductal adenocarcinoma of the pancreas affects survival after multimodal therapy.
    Safi SA; Lehwald-Tywuschik N; Rehders A; Fluegen G; Haeberle L; Keitel V; Knoefel WT
    BMC Surg; 2021 Mar; 21(1):110. PubMed ID: 33658016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of 4- and 4 plus-courses S-1 administration as adjuvant chemotherapy for pancreatic ductal adenocarcinoma.
    Li B; Shen S; You S; Zhang G; Gao S; Shi X; Wang H; Yin X; Xu X; Guo S; Jin G
    BMC Cancer; 2021 May; 21(1):612. PubMed ID: 34034684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of different metastatic patterns on survival in patients with pancreatic cancer.
    He C; Huang X; Zhang Y; Lin X; Li S
    Pancreatology; 2021 Apr; 21(3):556-563. PubMed ID: 33518454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of the location of pancreatic ductal adenocarcinoma (head, body, tail) with tumor stage, treatment, and survival: a population-based analysis.
    van Erning FN; Mackay TM; van der Geest LGM; Groot Koerkamp B; van Laarhoven HWM; Bonsing BA; Wilmink JW; van Santvoort HC; de Vos-Geelen J; van Eijck CHJ; Busch OR; Lemmens VE; Besselink MG;
    Acta Oncol; 2018 Dec; 57(12):1655-1662. PubMed ID: 30264642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of intraperitoneal chemotherapy in the surgical management of pancreatic ductal adenocarcinoma: a systematic review.
    Brind'Amour A; Webb M; Parapini M; Sidéris L; Segedi M; Chung SW; Chartier-Plante S; Dubé P; Scudamore CH; Kim PTW
    Clin Exp Metastasis; 2021 Apr; 38(2):187-196. PubMed ID: 33486670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients with hepatic oligometastatic pancreatic body/tail ductal adenocarcinoma may benefit from synchronous resection.
    Yang J; Zhang J; Lui W; Huo Y; Fu X; Yang M; Hua R; Wang L; Sun Y
    HPB (Oxford); 2020 Jan; 22(1):91-101. PubMed ID: 31262486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of neural invasion on survival and tumor recurrence in pancreatic ductal adenocarcinoma - A systematic review and meta-analysis.
    Schorn S; Demir IE; Haller B; Scheufele F; Reyes CM; Tieftrunk E; Sargut M; Goess R; Friess H; Ceyhan GO
    Surg Oncol; 2017 Mar; 26(1):105-115. PubMed ID: 28317579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative evaluation of pancreatic ductal adenocarcinoma with synchronous liver metastasis: Diagnosis and assessment of unresectability.
    Shi HJ; Jin C; Fu DL
    World J Gastroenterol; 2016 Dec; 22(45):10024-10037. PubMed ID: 28018110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors influencing receipt of adjuvant chemotherapy after surgery for pancreatic cancer: a two-center retrospective cohort study.
    Åkerberg D; Björnsson B; Ansari D
    Scand J Gastroenterol; 2017 Jan; 52(1):56-60. PubMed ID: 27598522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
    Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S
    BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Percutaneous Radiofrequency Ablation for Metachronous Hepatic Metastases after Curative Resection of Pancreatic Adenocarcinoma.
    Lee SJ; Kim JH; Kim SY; Won HJ; Shin YM; Kim PN
    Korean J Radiol; 2020 Mar; 21(3):316-324. PubMed ID: 32090524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metachronous hepatic resection for liver only pancreatic metastases.
    Schwarz C; Fitschek F; Primavesi F; Stättner S; Margonis GA; Weiss MA; Stavrou GA; Oldhafer KJ; Kornprat P; Wundsam H; Fischer I; Längle F; Függer R; Hauer A; Klug R; Kieler M; Prager G; Schindl M; Stremitzer S; Bodingbauer M; Sahora K; Kaczirek K
    Surg Oncol; 2020 Dec; 35():169-173. PubMed ID: 32889249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Driver Mutations on the Evolution of Isolated Metachronous Lung Metastasis of Pancreatic Ductal adenocarcinoma.
    Vitellius C; Griveaux O; Morvant B; Pedrono E; Venara A; Ingster O; Baize N; Dincuff E; Rousselet MC; Guardiola P; Caroli-Bosc FX
    Mol Diagn Ther; 2020 Aug; 24(4):443-449. PubMed ID: 32524539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study.
    Labori KJ; Katz MH; Tzeng CW; Bjørnbeth BA; Cvancarova M; Edwin B; Kure EH; Eide TJ; Dueland S; Buanes T; Gladhaug IP
    Acta Oncol; 2016; 55(3):265-77. PubMed ID: 26213211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synchronous resections of hepatic oligometastatic pancreatic cancer: Disputing a principle in a time of safe pancreatic operations in a retrospective multicenter analysis.
    Tachezy M; Gebauer F; Janot M; Uhl W; Zerbi A; Montorsi M; Perinel J; Adham M; Dervenis C; Agalianos C; Malleo G; Maggino L; Stein A; Izbicki JR; Bockhorn M
    Surgery; 2016 Jul; 160(1):136-144. PubMed ID: 27048934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.